Common Stock

Bionano Genomics Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument a single-molecule imager; Saphyr Chip a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition it offers testing and laboratory services comprising FirstStepDx PLUS a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder developmental delay and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS a genetic testing panel for patients who have experienced seizures infantile spasms encephalopathy or febrile seizures; PGx test which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego California.